Immunoassay method and device with magnetically susceptible bead capture

US10126296B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10126296-B2
Application numberUS-201113204109-A
CountryUS
Kind codeB2
Filing dateAug 5, 2011
Priority dateAug 5, 2010
Publication dateNov 13, 2018
Grant dateNov 13, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field.

First claim

Opening claim text (preview).

What is claimed is: 1. A magnetic immunosensing device for detecting an analyte in a sample, comprising: a sample entry port for receiving the sample, a sample entry chamber in fluid communication with the sample entry port; a dry reagent comprising magnetically susceptible beads coated with an antibody to the analyte in the sample, wherein the dry reagent is present in the device as a coating in the sample entry port or the sample entry chamber, and is dissolved into the sample upon receiving the sample in the sample entry port or the sample entry chamber; a first conduit comprising a first portion in fluid communication with the sample entry chamber; a substantially planar chip positioned in a second portion of the conduit in fluid communication with the first portion of the first conduit, the chip comprising: a sensing electrode positioned in the second portion of the first conduit to detect activity of an electroactive species caused by binding of the analyte to the antibody and generate a sensor response; and a conductivity sensor positioned in the second portion of the first conduit and adjacent to the sensing electrode to monitor a position of the sample within the second portion of the first conduit relative to the sensing electrode; a sample diaphragm in communication with the sample entry chamber via a second conduit, wherein the sample diaphragm is capable of forcing air through the second conduit causing the sample and the beads to move from the sample entry chamber into the second portion of the first conduit and over the chip; an analyzer comprising a motor driven plunger to move the sample through the conduit, wherein the analyzer is in contact with the sample diaphragm; and a magnet that is either a permanent magnet or an electromagnet having a magnetic field of greater than 0.1 Tesla, wherein the magnet is positioned proximate to the chip for attracting the beads in the second portion of the first conduit substantially proximate to the sensing electrode and substantially retaining the beads at the sensing electrode surface during removal of unbound sample and washing of the sensing electrode with a wash fluid. 2. The device of claim 1 , wherein the magnet is the permanent magnet. 3. The device of claim 1 , wherein the magnet is the electromagnet. 4. The device of claim 1 , wherein the sensing electrode is microfabricated. 5. The device of claim 1 , wherein the sample is selected from the group consisting of blood, plasma, serum, urine, interstitial fluid and cerebrospinal fluid. 6. The device of claim 1 , wherein the sample is amended with an anticoagulant. 7. The device of claim 1 , wherein the permanent magnet or the electromagnet is positioned in a non-coplanar position relative to said chip. 8. The device of claim 1 , wherein the permanent magnet is selected from the group consisting of samarium cobalt (SmCo) alloy, aluminum nickel cobalt alloy (AlNiCo) and ferrite. 9. The device of claim 1 , wherein the permanent magnet comprises neodymium iron boron (NdFeB) alloy. 10. The device of claim 1 , wherein the permanent magnet comprises Nd 2 Fe 14 B. 11. The device of claim 1 , wherein the permanent magnet or the electromagnet is a bulk magnet. 12. The device of claim 1 , wherein the permanent magnet or the electromagnet is a substantially cylindrical bulk magnet. 13. The device of claim 1 , wherein the permanent magnet or the electromagnet is a substantially cylindrical bulk magnet, having a diameter in the range of about 0.1 mm to about 5 mm and a length of about 0.1 mm to about 5 mm. 14. The device of claim 1 , wherein the permanent magnet or the electromagnet is positioned to yield a bead event horizon in the conduit in the range of up to about 200 μm from the region of the sensing electrode. 15. The device of claim 1 , wherein the beads comprise ferrite. 16. The device of claim 1 , wherein the beads comprise magnetite (Fe 3 O 4 ). 17. The device of claim 1 , wherein the beads comprise a magnetically susceptible core with a polymer coating. 18. The device of claim 1 , wherein the beads have an average particle size of from 0.01 μm to 20 μm. 19. The device of claim 1 , wherein the beads have an average particle size of from 0.1 μm to 5 μm. 20. The device of claim 1 , wherein the beads have an average particle size of from 0.2 μm to 1.5 μm. 21. The device of claim 1 , wherein the sensing electrode is amperometric. 22. The device of claim 1 , wherein the sensing electrode is a gold microarray. 23. The device of claim 1 , wherein the conduit has a height of about 0.2 mm to about 5 mm and a width of about 0.2 mm to about 5 mm. 24. The device of claim 1 , wherein the conduit has a uniform cross-sectional area. 25. The device of claim 1 , wherein the conduit has a non-uniform cross-sectional area. 26. The device of claim 1 , wherein the analyte is selected from the group consisting of cardiac troponin I, troponin T, a troponin complex, human chorionic gonadotropin, BNP, creatine kinase, creatine kinase subunit M, creatine kinase subunit B, creatine kinase MB (CK-MB), proBNP, NT-proBNP, myoglobin, myosin light chain, galectin-3, and modified fragments thereof. 27. The device of claim 1 , wherein the analyte is selected from the group consisting of beta-HCG, TSH, ultra hTSH II, TT3, TT4, FT3, FT4, myeloperoxidase, D-dimer, CRP, NGAL, PSA, LH, FSH, prolactin, progesterone, estradiol, DHEA-S, AFP, CA 125 II, CA 125, CA 15-3, CA 19-9, CA 19-9XR, CEA, thyroxine (T4), triiodothyronine (T3), T-uptake, Tg, anti-Tg, anti-TPO, ferritin, cortisol, insulin, HBsAg, HCV Ag/Ab combo, HCV core Ag, anti-HCV, AUSAB (anti-HBs), CORE, CORE-M, SHBG, iPTH, theophylline, sirolimus, tacrolimus, anti-HAV, anti-HAV IgM, HAVAB, HAVAB-M, HAVAB-M2.0, HAVAB-G, HAVAB 2.0, HAVAB 2.0 Quant, IgM, CMV IgM, CMV IgG, â-2-microglobulin, digitoxin, HBe, anti-HBe, HBeAg, HIV 1/2gO, HIV Ag/Ab combo, testosterone, SCC, vitamin B12, folate, syphilis, anti-HBc, rubella IgG, rubella IgM, homocysteine, MPO, cytomegalovirus (CMV) IgG Avidity, toxo IgG avidity, toxo IgG, toxo IgM, C-peptide, vitamin D, HTLV I/II, total âhCG, progesterone, estradrogen, prolactin, myoglobin, tPSA, fPSA, carbamazepine (CBZ), digoxin, gentamicin, NAPA, phenytoin, phenobarbital, valproic acid, vancomycin, procaine, quinidine, tobramycin, methamphetamine (METH), amphetamine (AMPH), barbituates, benzodiazepine, cannabis, cocaine, methadone, opiates, PCP, acetaminophen, ethanol, salicylates, tricyclics, holoTc, anti-CCP, HbA1c, barbs-U and modified fragments thereof. 28. A kit for performing an analyte immunoassay in a whole blood sample, comprising: a magnetic immunosensing device comprising: a sample entry port for receiving the sample, a sample entry chamber in fluid communication with the sample entry port; a dry reagent comprising magnetically susceptible beads coated with an antibody to the analyte in the sample, wherein the dry reagent is present in the device as a coating in the sample entry port or the sample entry chamber, and is dissolved into the sample upon receiving the sample in the sample entry port or the sample entry chamber; a first conduit comprising a first portion in fluid communication with the sample entry chamber; a substantially planar chip positioned in a second portion of the conduit in fluid communication with the first portion of the first conduct, the chip comprising: a sens

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10126296B2 cover?
The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field.
Who is the assignee on this patent?
Miller Cary James, Abbott Point Of Care Inc
What technology area does this patent fall under?
Primary CPC classification G01N33/54326. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).